Irritable bowel syndrome: Toward an understanding of severity

被引:84
作者
Lembo, A
Ameen, VZ
Drossman, DA
机构
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
[3] Univ N Carolina, UNC Ctr Funct GI & Motil Disorders, Chapel Hill, NC USA
关键词
D O I
10.1016/S1542-3565(05)00157-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Irritable bowel syndrome (IBS) is a chronic disorder with symptoms that range in severity from mild and intermittent to severe and continuous. Although severity is a guiding factor in clinical decision making related to diagnosis and treatment, current guidelines related to IBS do not address the. issue of severity. Recent data suggest that severity as a multidimensional concept, not fully explained by intensity of symptoms, has important clinical implications including health care utilization and health-related quality of life. Components of IBS severity include symptom intensity, time of assessment, whether the patient or physician makes the severity determination, the type of scale used to measure severity, and the degree of disability or impairment. Currently no consensus definition of IBS severity exists, although 2 validated scales of IBS severity have recently been published. Review of the literature suggests that the prevalence of severe or very severe IBS is higher than previously estimated with a range from 3%-69%. Individual IBS symptoms are important but are not sufficient to explain severity. Rather, severity has multiple components including health-related quality of life, psychosocial actors, health care utilization behaviors, and burden of illness. However, studies have not been adequately designed to determine the relative values of these factors in IBS severity.
引用
收藏
页码:717 / 725
页数:9
相关论文
共 42 条
[1]  
AMEEN V, 2004, AM J GASTROENTEROL, V99, pA844
[2]   Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome [J].
Coffin, B ;
Dapoigny, M ;
Cloarec, D ;
Comet, D ;
Dyard, F .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2004, 28 (01) :11-15
[3]  
Creed F, 1999, AM J MED S5A, V107, p74S, DOI DOI 10.1016/S0002-9343(99)00083-2
[4]   Perceptions of Physicians and Patients With Organic and Functional Gastrointestinal Diagnoses [J].
Dalton, Christine B. ;
Drossman, Douglas A. ;
Hathaway, Joseph M. ;
Bangdiwala, Shrikant I. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (02) :121-126
[5]   Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders [J].
Drossman, DA ;
Toner, BB ;
Whitehead, WE ;
Diamant, NE ;
Dalton, CB ;
Duncan, S ;
Emmott, S ;
Proffitt, V ;
Akman, D ;
Frusciante, K ;
Le, T ;
Meyer, K ;
Bradshaw, B ;
Mikula, K ;
Morris, CB ;
Blackman, CJ ;
Hu, YM ;
Jia, HG ;
Li, JZ ;
Koch, GG ;
Bangdiwala, SI .
GASTROENTEROLOGY, 2003, 125 (01) :19-31
[6]  
Drossman DA, 2002, GASTROENTEROLOGY, V123, P2108, DOI 10.1053/gast.2002.37095
[7]   Health status by gastrointestinal diagnosis and abuse history [J].
Drossman, DA ;
Li, ZM ;
Leserman, J ;
Toomey, TC ;
Hu, YMJB .
GASTROENTEROLOGY, 1996, 110 (04) :999-1007
[8]   FUNCTIONAL BOWEL DISORDERS - A MULTICENTER COMPARISON OF HEALTH-STATUS AND DEVELOPMENT OF ILLNESS SEVERITY INDEX [J].
DROSSMAN, DA ;
LI, ZM ;
TONER, BB ;
DIAMANT, NE ;
CREED, FH ;
THOMPSON, D ;
READ, NW ;
BABBS, C ;
BARREIRO, M ;
BANK, L ;
WHITEHEAD, WE ;
SCHUSTER, MM ;
GUTHRIE, EA .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (05) :986-995
[9]   THE IRRITABLE-BOWEL-SYNDROME - REVIEW AND A GRADUATED MULTICOMPONENT TREATMENT APPROACH [J].
DROSSMAN, DA ;
THOMPSON, WG .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (12) :1009-1016
[10]  
Drossman DA, 2000, AM J GASTROENTEROL, V95, P999